在患有晚期甲状腺癌的患者中,TP53的变化与对伦瓦替尼的反应不佳有关
Valentina Cirello1,2, Carla Colombo1,2, Delfina Tosi3
1Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy.
The Journal of clinical endocrinology and metabolism
|February 1, 2025
概括
在晚期甲状腺癌中,TP53突变预示着对lenvatinib的反应不佳. 患有TP53变化的患者经历了较短的无进展和整体存活时间,突出了治疗选择的潜在生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 关于TP53突变与甲状腺癌 (TC) 中的多酶抑制剂 (MKI) 反应之间的关联存在有限的数据.
- 了解MKI治疗的预测生物标志物对于优化高级TC患者的治疗结果至关重要.
研究的目的:
- 调查TP53突变对先进TC中伦瓦丁尼布 (LEN) 反应的影响.
- 为了评估TP53状态作为伦瓦提尼布治疗疗效的预测生物标志物在体外和患者队列中.
主要方法:
- 在30个先进的TC瘤组织中分析TP53突变和p53蛋白质表达,这些组织来自用伦瓦提尼布治疗的患者.
- 分子形状与临床病理特征和伦瓦替尼的反应的相关性.
- 在TP53-缺陷和TP53-良好的TC细胞系中对伦瓦提尼布敏感性的体外评估.
主要成果:
- TP53突变与伦瓦提尼布反应不佳有显著的相关性 (p=0.005).
- 患有TP53突变的患者表现出明显较短的无进展生存期 (PFS) 和总生存期 (OS) (分别p<0.0001和p=0.0007).
- 改变的核p53蛋白表达也预测了更短的PFS和OS,与TP53-突变细胞系的发现一致.
结论:
- TP53的改变是先进的TC中伦瓦替尼对伦瓦替尼反应不佳的重要预测因素.
- 在开始MKI治疗之前,对TP53突变和p53表达的评估可能有助于患者分层.
- 这项研究为TP53在甲状腺癌中伦瓦提尼布耐药性的作用提供了新的见解.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K


